Streetbeat News

Regulatory

ADAP

Adaptimmune's lete-cel achieved the primary endpoint in a pivotal trial for synovial sarcoma and MRCLS, with 42% of patients showing clinical responses. The company plans a rolling BLA submission by the end of 2025.

Portfolio Pulse from

November 13, 2024 | 2:15 pm

AMLP

The Trump Administration's pro-oil policies and potential regulatory rollbacks are expected to benefit the pipeline industry, making Alerian MLP ETF (AMLP) an attractive option for income-focused investors due to its substantial dividends and capital appreciation.

Portfolio Pulse from

November 13, 2024 | 2:15 pm

PEGRY

UBS anticipates potential dividend cuts for water utilities following the upcoming Ofwat price regime decision. Pennon Group is expected to be affected, with less certainty for United Utilities and Severn Trent.

Portfolio Pulse from

November 13, 2024 | 2:15 pm

NVEI

Nuvei Corporation has received all necessary regulatory approvals for its going private transaction with Neon Maple Purchaser Inc., backed by Advent International and other investors. The transaction is expected to close around November 15, 2024.

Portfolio Pulse from

November 13, 2024 | 2:00 pm

SVRE

SaverOne 2014 Ltd. has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market.

Portfolio Pulse from

November 13, 2024 | 2:00 pm

OPAL

OPAL Fuels, a vertically integrated RNG producer, is experiencing significant revenue growth and increased production capacity despite a 30% YTD stock price decline. The RNG market is projected to grow significantly, and OPAL's diversified business and improved margins support a 'buy' rating.

Portfolio Pulse from

November 13, 2024 | 1:45 pm

PACS

Johnson Fistel, LLP is investigating PACS Group, Inc. for potential securities law violations following a critical report by Hindenburg Research. The report accuses PACS of misrepresenting its turnaround strategy for skilled nursing facilities.

Portfolio Pulse from

November 13, 2024 | 1:15 pm

AIMD

Ainos, Inc. has received IRB approval for its VELDONA clinical trial for primary Sjogren's syndrome, with Taiwan FDA approval expected in Q1 2025. The company remains committed to a capital-efficient strategy.

Portfolio Pulse from

November 13, 2024 | 1:15 pm

PHRRF

PharmaTher Holdings Ltd. has been granted a post-complete response letter clarification meeting with the FDA regarding their ketamine Abbreviated New Drug Application. This follows a complete response letter issued by the FDA in October 2024.

Portfolio Pulse from

November 13, 2024 | 1:15 pm

THAR

Tharimmune, Inc. has been granted a European patent for its biodegradable polymeric nanoparticles, enhancing delivery of therapeutic antibodies and peptides, particularly in cancer therapies.

Portfolio Pulse from

November 13, 2024 | 1:15 pm